The investigation of the Nightingale account begins with a practical mystery: who is paying for Holly Walsh’s costly treatment, and is that money connected to Jane Glasson’s disappearance? As Blake and Don follow the payments, a seemingly personal act of generosity opens onto the opaque finances of Harkness Pharmaceuticals. The inquiry does not establish that Jane is the benefactor; instead, it uncovers a different donor’s identity and motive, while showing how little the account explains about the larger sums allegedly diverted from Harkness’s business.

The treatment and the anonymous account

Don first encounters the clue through Holly’s blog posts. Holly lives in Hampshire, has multiple sclerosis, and writes about managing the disease with an experimental drug she calls the Wonderpill. She credits an anonymous benefactor with making the treatment affordable and describes the improvement as life-changing. Her posts thank a secret saviour, but offer no explanation that accounts for why Andrew Glasson had drawn Holly to Don’s attention. Don therefore brings the material to Blake rather than treating the blog as proof of a connection to Jane.

The medicine itself makes the possible connection to Harkness difficult to ignore. During a visit, Blake notices cartons of Ditrimantelline in Holly’s bathroom cabinet, marked as a daily 10-milligram treatment and carrying the Harkness Pharmaceuticals name. The same cabinet contains Elixtris face cream and body scrub. The ordinary products and prescription medicine sit together in a domestic space; for Blake, their labels make Harkness feel inescapably present in Holly’s life. The treatment is not merely a clue in a financial inquiry: Holly depends on it, and Anna Marchant describes its effects as transformative.

Blake raises the possibility that Jane is funding the supply. Holly acknowledges that the anonymous payments made her wonder, but rejects the conclusion. To believe Jane responsible, she says, would mean believing that Jane deliberately abandoned her family and friends when she disappeared twenty-two years earlier. Holly cannot reconcile that explanation with her understanding of Jane. Anna is even more determined to prevent the suggestion from taking hold, stepping in to argue that people may do good without seeking recognition. Her protectiveness complicates the interview: the investigators are pursuing a legitimate lead, but further probing risks unsettling Holly and threatening the stability that treatment has helped restore.

Tracing the name Luscinia

Holly identifies the payment route as an account at Credit Suisse in London, held in the name Nightingale. The bank will not say whether that is the name of a person or a company. The benefactor first contacted Holly by email under the name Luscinia. Holly understands that it is probably an alias: the word means nightingale in Latin. The correspondence said the sender worked in pharmaceuticals, objected to the high cost of effective drugs, had read Holly’s accounts of living with multiple sclerosis, and wanted to supply Ditrimantelline anonymously because disclosure could cause trouble.

Anna initially resists revealing more, but later offers to meet Blake and Don privately. She then confirms that she met Luscinia at a coffee shop in O’Hare Airport. The benefactor is not Jane Glasson but an Asian American woman in her mid-thirties who inherited a fortune from her father and uses some of it for charitable purposes. Anna gathered that the woman’s wealthy husband might disapprove of her giving, although the woman disclosed little about her present circumstances. Holly is not her only beneficiary.

Anna also explains the personal history behind the giving. The benefactor’s brother died as a child because he could not obtain proper medical treatment. By then their parents had divorced, and their mother was nearly penniless and unable to afford the drugs he needed. The benefactor now helps people facing similar circumstances when she can. Anna glimpsed the woman’s name on a credit card and later searched for information about her husband and father, but refuses to pass those details on. She considers the donor entitled to privacy, and says she disclosed the story only because she wants the investigators to stop putting Holly’s health at risk. The revelation resolves one question while setting a limit on how far the investigation can ethically pursue the donor.

A creditor’s inquiry and the risk to Holly

Holly also tells Blake and Don that a private investigator had contacted her a couple of weeks earlier and then visited. He knew that she received money from the Nightingale account and wanted to know why. Anna had favoured refusing to answer, but Holly explained what the money paid for. The investigator did not mention Jane, and Holly judged that he knew nothing about her; his interest appeared to lie elsewhere. He was working for some of Harkness’s creditors, though he did not confirm this directly.

That visit gives the payments a more precarious meaning. Holly fears that Luscinia might be a Harkness employee diverting company funds to pay for her medication. If so, the supply could be stopped. The investigator reassured her that nothing was likely to happen until Jack Harkness’s case had gone through the American courts, a process that could take years if he were extradited. The reassurance is provisional rather than a guarantee: Holly’s access to treatment may depend on the outcome of legal proceedings in which she has no control.

The episode thus places a vulnerable patient inside a conflict among anonymous charity, corporate funds, creditors, and criminal allegations. Holly’s treatment has markedly improved her life, but its funding trail is hidden behind an account whose owner the bank will not identify and a donor who insists on privacy. The same opacity that protects a benefactor also makes the source of money difficult to assess.

The account within Harkness’s wider finances

The later financial investigation gives the Nightingale account a sharply limited place in the larger Harkness mystery. Jack Harkness took control of Furgler Pharmaceuticals after Lenore Furgler sold him the company in 1995; it became Harkness Pharmaceuticals and grew into a major drug and beauty-products business. The account’s connection to the company is therefore plausible enough to investigate, especially since Ditrimantelline is labelled as a Harkness product. Yet the label alone does not prove who manufactured the contents: Anna points out that an independent laboratory might supply the drug.

The investigators also learn that Quintagler Industries alleges Harkness diverted money over several years into subsidiaries of shell companies ultimately owned by him. Those companies are also alleged to have supplied funds for bribes to doctors. The alleged bribes account for only a fraction of the missing money; the rest remains unlocated. Against billions of dollars allegedly involved, the London Nightingale account is described as a one-off and comparatively small. It offers a traceable payment and a humane explanation, but does not reveal what happened to the much larger sums.

Other financial anomalies deepen the distinction between a visible charitable payment and Harkness’s concealed projects without proving that they share a source. Mike Coleman tells Don that Harkness arranged an excessive independent power system for Wortalleth West: a solar array, inconspicuous photovoltaic film, and a large flow battery whose location Coleman cannot find. Later, investigators confront Filippo Crosetti over Harkness Pharmaceuticals’ funding of research in nanotechnology and bioelectronics, including additional funding with no apparent booked source. The eventual disclosure that the company’s products have carried nanobots for years gives those research expenditures a purpose, but the evidence does not establish that the Nightingale payments financed that programme.

The account’s importance lies in this contrast. Holly’s treatment turns pharmaceutical supply into an intimate matter of illness, care, and dependence; the investigation then follows money into corporate structures designed to obscure responsibility. Luscinia’s disclosed motive is rooted in a child’s inability to obtain medicine, while the wider Harkness inquiry concerns alleged diversion on a vastly greater scale and research kept from ordinary view. Blake and Don identify a plausible benefactor and the limits of what she will reveal, but the Nightingale trail remains a narrow window onto a much larger financial darkness.